KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Hold” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been given an average recommendation of “Hold” by the nine analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $30.60.

KALV has been the topic of a number of recent analyst reports. HC Wainwright reissued a “neutral” rating and set a $27.00 target price (down from $37.00) on shares of KalVista Pharmaceuticals in a report on Friday. Stifel Nicolaus boosted their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Leerink Partners lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for $27.00 per share in cash (~$1.9B), creating a clear-cash exit and explaining the stock’s run-up on the takeover premium. Chiesi to buy KalVista in $1.9B deal for rare disease drug
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating and cut its price target to $27 from $37, signaling limited upside vs. the deal price but keeping stance unchanged. Benzinga
• Negative Sentiment: Several brokerages (Needham, JonesTrading, Leerink, Citizens Jmp) downgraded KalVista from buy/strong-buy to hold, reducing buy-side analyst enthusiasm and potentially limiting upward momentum ahead of/around deal close. Zacks
• Negative Sentiment: Shareholder-law firms Kahn Swick & Foti and Halper Sadeh announced investigations into whether the $27 per share consideration and the sale process are fair, introducing legal and timing risk that could complicate or delay the transaction and create downside volatility. KalVista Investor Alert: Kahn Swick & Foti Investigates Halper Sadeh investigation report
• Neutral Sentiment: Elevated trading volume and the stock trading near its 52‑week high reflect deal-driven activity; with the $27 cash offer effectively setting a takeover price, remaining movement will hinge on deal completion timing and any litigation or regulatory hurdles. (See aggregated news coverage.) MSN coverage

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. The trade was a 7.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $156,229.38. Following the transaction, the chief executive officer directly owned 442,883 shares in the company, valued at $6,895,688.31. The trade was a 2.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 263,969 shares of company stock worth $4,536,178 in the last three months. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $55,000. Wolverine Asset Management LLC acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $57,000. Truvestments Capital LLC grew its holdings in KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $63,000.

KalVista Pharmaceuticals Trading Down 0.0%

Shares of KalVista Pharmaceuticals stock opened at $26.65 on Friday. KalVista Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $26.76. The stock has a market cap of $1.37 billion, a P/E ratio of -6.75 and a beta of -0.12. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The business’s 50 day moving average is $18.45 and its 200-day moving average is $15.75.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.